Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Tara V. Anand et al.|Journal of the American College of Cardiology|2024Cited by 33
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Paul Nagy et al.|BMJ Medicine|2023Cited by 27
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and BevacizumabCindy X. Cai, Patrick Ryan, Scott L. Zeger et al.|Ophthalmology Retina|2024Cited by 16